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Abstract
Background: HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ),
a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by
frequent co-expression of EGFR and by sustained activation of the mammalian target of rapamycin (mTOR)
pathway. Here, we assessed feasibility of combining the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus
(RAD001) for treating HER2 overexpressing breast cancers with different sensitivity to TZ.
Methods: The gefitinib and RAD001 combination was broadly evaluated in TZ sensitive (SKBR3 and MCF7-HER2)
and TZ resistant (JIMT-1) breast cancer models. The effects on cell growth were measured in cell based assays
using the fixed molar ratio design and the median effect principle. In vivo studies were performed in Rag2M mice
bearing established tumors. Analysis of cell cycle, changes in targeted signaling pathways and tumor characteristics
were conducted to assess gefitinib and RAD001 interactions.
Results: The gefitinib and RAD001 combination inhibited cell growth in vitro in a synergistic fashion as defined by
the Chou and Talalay median effect principle and increased tumor xenograft growth delay. The improvement in
therapeutic efficacy by the combination was associated in vitro with cell line dependent increases in cytotoxicity
and cytostasis while treatment in vivo promoted cytostasis. The most striking and consistent therapeutic effect of
the combination was increased inhibition of the mTOR pathway (in vitro and in vivo) and EGFR signaling in vivo
relative to the single drugs.
Conclusions: The gefitinib and RAD001 combination provides effective control over growth of HER2
overexpressing cells and tumors irrespective of the TZ sensitivity status.
Background
HER2 overexpression is present in 13-30% of all breast
cancers [1,2] and it correlates with poor disease out-
come, high rates of metastasis and resistance to conven-
tional treatment modalities [1-5]. Trastuzumab (TZ;
Herceptin
®), a monoclonal antibody that targets the
HER2 receptor and interferes with its function is
effective in treating some HER2-positive breast cancers
[6-8]. However, many patients with HER2-positive dis-
ease are insensitive to TZ both as first line treatment or
following a relapse after conventional chemotherapy
[6-9]. Furthermore, the majority of patients with meta-
static disease that initially respond to TZ ultimately
develop clinically relevant resistance to this agent [8,9].
As TZ treatment has recently been expanded into the
adjuvant setting [10], intrinsic and acquired resistance
represents an important clinical problem that urgently
awaits a discovery of novel drugs and development of
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patients with advanced HER2-positive and TZ refractory
disease.
Numerous studies have demonstrated that HER2 is
often co-expressed in breast cancers with epidermal
growth factor receptor (EGFR) [1,5,8,11-16]. It has been
established that dimerization of HER2 and EGFR gener-
ates a potent signaling response mediated primarily
through activation of the phosphatidylinositol 3-kinase
(PI3K)/AKT and the RAS-Raf-mitogen-activated protein
kinase (MAPK) pathways that sustain cancer cell
growth, proliferation and survival [5,8]. Co-expression of
EGFR and HER2 in breast cancer cell lines has been
shown to induce drug resistance, including resistance to
TZ [17,18], and has been correlated with a negative
prognosis for breast cancer patients [1,11]. These data
suggested that EGFR constitutes an important therapeu-
tic target in breast cancers and have prompted investiga-
tors to consider gefitinib (ZD1839, Iressa
®), a reversible
small molecule inhibitor of the EGFR tyrosine kinase,
for treatment of HER2 overexpressing and EGFR co-
expressing breast malignancies [19].
The preclinical data have demonstrated that gefitinib
exerts positive therapeutic effects in models of HER2
overexpressing breast cancer which have been attributed
to blocking activity of the PI3K/AKT and the MAPK
pathways, increased apoptosis, induction of cytostasis
through G1/G0 cell cycle arrest and downregulation of
cyclin D1, as well as inhibiting angiogenesis
[12-14,20,21]. However, our previous study conducted in
animals bearing HER2 overexpressing MCF7-HER2 and
MDA-MB-435/LCC6-HER2 breast cancer xenografts
showed that gefitinib monotherapy results in only mod-
est reduction of tumor volume [12]. The same study
also showed that when gefitinib was used in combina-
tion with TZ the in vivo efficacy has been improved as
judged by inhibition of tumor growth, but the data
obtained by measuring multiple endpoints of therapeutic
activity revealed that the combination was not beneficial
[12]. These results have been recapitulated in a clinical
trial demonstrating that the TZ and gefitinib combina-
tion should not be used for treatment in patients with
HER2-positive breast cancer [19].
More recently, it has been shown that HER2 overex-
pression in breast cancer is often associated with aber-
rant activation of the mTOR pathway [22,23]. mTOR is
a major cellular signaling hub that integrates inputs
from the upstream signaling pathways, including tyro-
sine kinase receptors, while also governing energy
homeostasis and cellular responses to stress such as
nutrient deprivation and hypoxia [24,25]. The mTOR
kinase liaisons with either Raptor or Rictor proteins to
form two functionally different complexes: rapamycin-
sensitive mTOR complex 1 (mTORC1) and rapamycin-
insensitive mTOR complex 2 (mTORC2) [24,25]. The
most prominent downstream effectors of mTORC1
include ribosomal S6 kinase (S6K) and the eukaryotic
translation initiation factor 4E-binding protein 1 (4E-
BP1) which regulate the translation of ribosomal and
cap-dependent proteins essential for cell growth and G1
to S cell cycle progression [24,25]. mTORC2 is an Akt
Ser473 kinase that is controlled by a feedback inhibitory
loop mediated through S6K1 (p70S6K) [24-29]. Because
of its critical role in promoting cell growth, mTOR is
considered an attractive target in cancer [25,30]. Everoli-
mus (RAD001) and CCI-779 are two allosteric mTORC1
inhibitors that are in clinical development for various
malignancies; however, single-agent therapy has only
modest efficacy in the metastatic breast cancer setting
[31,32]. These results have encouraged the investigation
of mTORC1 inhibitors in combination with other tar-
geted therapies such as aromatase inhibitors and HER2
targeting drugs. A Phase I/II trial of RAD001 in combi-
nation with TZ in refractory HER2 positive metastatic
breast cancer have reported encouraging results with
34% of patients achieving clinical benefit [33]. Interest-
ingly, several preclinical studies documented that mTOR
inhibitors combined with EGFR targeted agents increase
efficacy of treatment in renal, lung, pancreatic, colon,
prostate and HER2-negative breast cancer models
[34-36]. However, the therapeutic effects of EGFR and
mTOR inhibitors in combination have not yet been
broadly assessed in HER2 overexpressing breast cancers
with different TZ sensitivity. Here, we show that the
EGFR inhibitor gefitinib and the mTOR inhibitor
RAD001 when used in combination improve effective-
ness of the treatment in HER2 overexpressing breast
cancers that results in impediment of cancer growth.
Methods
Cells, tumor xenografts and treatments
MCF7-HER2 cells were a gift from Dr. M. Alaoui-Jamali
(McGill University, Montreal, Quebec, Canada) [37],
SKBR3 cells were purchased from American Type Cul-
ture Collection (ATCC) and JIMT-1 cells [38] were pur-
chased from German Collection of Microorganisms and
Cell Culture (Deutsche Sammlung von Mikroorganis-
men und Zellkulturen GmbH (DSMZ). All cell lines
were tested Mycoplasma negative by PCR reaction.
MCF7-HER2 cells were maintained in RPMI, SKBR-3 in
McCoy’s 5A and JIMT-1 in DMEM supplemented with
L-glutamine and 10% fetal bovine serum. For in vivo
studies JIMT-1 and MCF7-HER2 cells were harvested in
the exponential growth phase and 5 × 10
6 (JIMT-1) or 1
×1 0
7 (MCF7-HER2) cells were injected subcutaneously
(s.c.) on the back of female Rag2M immuno-compro-
mised mice. Mice receiving MCF7-HER2 cells were
implanted with 17-b-estradiol 60-day release tablets
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Tumor growth was monitored twice a week; tumor sizes
were calculated using the formula: 0.5 [length (mm)] ×
[width (mm)
2]. All agents were delivered as oral gavage.
Treatment was initiated on day 17 and carried-out
Monday through Friday (QDx5) for 28 (JIMT-1) or 25
(MCF7-HER2) days. RAD001 (a generous gift from
Novartis) was diluted with vehicle (Novartis, content not
disclosed) and aliquots were kept frozen for the course
of treatment. RAD001 and vehicle aliquots were thawed
10-30 min before dosing animals and unused portions
were discarded. Gefitinib (a generous gift from AstraZe-
neca) was solubilized in 0.5% Tween-80 in sterile milli-
Q water (vehicle) and kept at 4°C. Gefitinib formulation
was prepared weekly. Combination treated mice were
dosed first with gefitinib followed by RAD001 four
hours later. Tumors were harvested 30 min after the last
dose and cut into two parts: one part was frozen in
liquid nitrogen (N2)f o rW e s t e r nb l o ta n a l y s i sa n dt h e
second part was frozen in embedding medium and
stored in -80°C for immunohistochemical processing.
Animal protocols were approved by the University of
British Columbia Animal Care Committee, and these
studies were done in accordance with guidelines estab-
lished by the Canadian Council on Animal Care.
Alamar Blue and IN Cell 1000 screening assays
Cells were plated under standard serum conditions (10%
FBS) in their respective media in triplicate wells/condi-
tion in 96-well flat bottom plates (Optilux, Falcon, Bec-
ton-Dickinson). MCF7-HER2 and JIMT-1 cells were
plated at densities of 5,000 or 1,500 cells/well for 72 and
144 h drug incubations, respectively. SKBR3 cells were
plated at 15,000 and 4000 cells/well for 72 and 144 h,
respectively. Cells were allowed to adhere overnight.
Next day the cells were treated with gefitinib, RAD001
and combination of both drugs at a fixed molar ratio
over a broad dose range to establish growth curves for a
72 h and 144 h read-out. Stock solutions of 20 mM gefiti-
nib and 20 mM RAD001 were prepared in DMSO and
stored in -80°C. Gefitinib and RAD001 stocks were
diluted in medium with decreasing percentage of DMSO
and 10× concentrated drugs were added to cells. The
final concentration of DMSO in vehicle and drug treated
cells was standardized to 0.5% (vol/vol) and the final
media volume in 96-well plate wells was 200 μl. After 72
or 144 h incubation, Alamar Blue (Invitrogen, Burlington,
ON, CA) was added to one set of plates to evaluate cell
viability. Fluorescence was measured using the FLUOstar
OPTIMA plate reader (BMG Labtechnologies, Germany)
with 544 nm excitation and 590 nm emission filters. A
second set of plates was stained with DRAQ5 (Biostatus,
Shepshed, UK) and ethidium homodimer (ETH; Molecu-
lar Probes, Invitrogen) followed by imaging with IN Cell
1000 Analyzer (GE Healthcare). Ten images per well
were acquired with 10× objective. Data analysis strategies
were supported by enterprise level servers. Images were
analyzed with IN Cell 1000 Investigator software using
the Multi Target Analysis (MTA) module and data were
reported as the percentage of dead cells normalized to
vehicle control by subtracting the percentage of dead
cells in the DMSO control from the percentage of dead
cells in treated cultures.
Synergy Determination
Following drug treatment in vitro, the number of viable
cells was measured using the Alamar Blue assay as
described above. Alamar Blue measures mitochondrial
activity which is lost upon cell death. The data obtained
with the Alamar Blue assay were normalized to the vehicle
control and expressed as % viability. Next, these data were
converted to Fraction affected (Fa; range 0-1), where Fa =
0 represents 100% viability and Fa = 1 represents 0% viabi-
lity) and analyzed with the CompuSyn™ program (Biosoft,
Ferguson, MO) based upon the Chou and Talalay median
effect principle [39]. This program calculates a combina-
tion index (CI) that is used to identify synergistic, additive,
and antagonistic drug interactions.
Flow cytometry
Cells were plated in their respective media containing
10% FBS in T25 flasks or 6 cm diameter culture dishes
and allowed to adhere overnight. The next day cells were
treated with the indicated agents. After 72 h, supernatant
from treated cells was transferred to a 14 ml tube and
combined with adherent cells harvested with 0.25% Tryp-
sin EDTA. For cell cycle analysis cells were washed twice
with PBS and 2 × 10
6 cells/sample were fixed in 1.8 ml
cold (-20°C) 70% ethanol followed by 1 h incubation on
ice and 24 h incubation in -20°C. Cells were then pelleted
and stained in PBS buffer containing 50 μg/ml propidium
iodide (PI, Molecular Probes, Invitrogen) with 1 mg/ml
RNase A (Sigma-Aldrich) and 0.1% Triton X-100 (Bio-
Rad, Richmond, CA) for 15 min at 37°C followed by 1 h
incubation on ice. For apoptosis analysis cells were
washed twice with Hank’s media without phenol red and
pellets were resuspended in Annexin-V buffer containing
anti-Annexin-V-FITC antibody (Caltag Laboratories,
Burlingame, CA). Samples were then incubated on ice for
30 min and counterstained with PI at a final concentra-
tion of 1 μg/ml. Flow cytometric analysis was performed
with FACSCalibur flow cytometer and acquired data
were analyzed with the Cellquest software (Becton-Dick-
inson, San Jose, CA).
Western blotting
Cells were plated in T25 flasks or 6 cm culture dishes
and after overnight adhesion treated with the indicated
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Cell pellets were lysed in lysis buffer containing 50 mM
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxy-
cholate, 1 mM EDTA, 0.1% SDS, and Mini Protease
Inhibitor Cocktail tables (Roche Diagnostics, Mannheim,
Germany). Tumors were homogenized in lysis buffer
followed by sonication. After centrifugation (30 min at
13000 rpm) the protein concentration in the superna-
tant was quantified using the Pierce Micro BCA™
Assay Kit. 30 - 50 μg of total protein per sample was
separated on precast 4-12% Bis-Tris gels (NuPage, Invi-
trogen) and transferred to NuPage 0.45 μm nitrocellu-
lose membranes (Invitrogen). Membranes were blocked
with 5% skim milk powder in TBS-T (150 mM NaCl, 50
mM Tris, 0.1% Tween-20, pH 7.4) and incubated over-
night with primary antibodies in 5% BSA in TBS-T. The
next day membranes were washed 3 times with TBS-T
and incubated for 1 h with peroxidase-conjugated sec-
ondary antibodies (Promega) in TBS-T containing 5%
skim milk. Membranes were washed 3 times with TBS-
T and signals were detected by enhanced chemilumines-
cence (SuperSignal
® West Pico Chemiluminescent Sub-
strate, Thermo Scientific) on BioMax Light Film
(Kodak). All antibodies used for Western blot analysis
were from Cell Signaling Technology (Beverly, MA).
The following phospho-specific antibodies were used: P-
EGFR (Tyr1086 antibody #2220), P-HER2 (Tyr1221/
1222 antibody #2243 or Tyr1248 antibody #2247), P-
ERK1/2 (Thr202/Tyr204 antibody #9101), P-AKT
(Ser473 antibody #4060), P-70S6K (Thr389 antibody
#9206), P-ribosomal protein S6 (Ser235/236 antibody
#2211). The b-actin antibody (Sigma-Aldrich) was used
as a loading control. Films with visualized protein bands
were digitized and the optical density (OD) of bands
was measured using UN-SCAN-IT graph and gel digitiz-
ing software (Silk Scientific, Inc.). After background sub-
traction the optical density (OD) value for each
individual protein band was corrected for b-actin load-
ing and normalized to the vehicle control expressed as l.
Western blot analysis was repeated 2 - 3 times to assure
consistency of the results.
Immunohistochemistry, image acquisition and image
analysis
10 μm cryosections were cut using a Cryostar HM560
(Microm International GmbH), air dried and then fixed
in 50% (v/v) acetone/methanol for 10 min at room tem-
perature. Endothelial cells were stained using a mono-
clonal antibody to PECAM/CD31 (BD Pharmingen) and
fluorescent Alexa 647 seconda r ya n t i b o d y( I n v i t r o g e n ) .
Terminal deoxyribonucleotide transferase-mediated
nick-end labeling (TUNEL) staining was used to label
apoptotic cells (In situ Cell Death Detection kit, TMR
red; Roche). Proliferating cells were stained using a
polyclonal antibody to Ki67 (AbCam) followed by a per-
oxidase conjugated secondarya n t i b o d y( S i g m a - A l d r i c h )
and metal-enhanced 3,3’-diaminobenzidine substrate
(Pierce). Cell nuclei were labeled with Hoechst 33342 (8
ng/mL; Molecular Probes, Invitrogen) for 30 min at 37°
C. At each stage of staining, whole tumor sections were
imaged using a robotic fluorescence microscope, as pre-
viously described [40,41]. Automated tiling of adjacent
microscope fields of view was completed to generate
images of an entire tumor section at a resolution of 0.75
μm per pixel. All parameters stained on the same sec-
tion were imaged separately using a monochrome cam-
era and composite color images were generated using
Adobe Photoshop (CS). Using NIH-Image http://rsb.
info.nih.gov/nih-image and user-supplied algorithms,
digital images were superimposed, aligned and cropped
to tumor tissue boundaries with staining artifacts
removed. Confluent necrosis was subsequently cropped
from images and the degree of necrotic tissue calculated
as the proportion of necrotic pixels relative to all pixels.
ImageJ software applications http://rsb.info.nih.gov/ij/
and user-supplied algorithmsw e r eu s e dt oq u a n t i f yt h e
degree of staining above the thresholds determined to
be > 10 standard deviations from background for CD31,
TUNEL and Ki67, and data are reported as percent
positive pixels of non-necrotic, viable tumor tissue. As a
measure of tumor vascularization, the median distance
of viable tissue to the nearest CD31-positive object
(blood vessel) is reported (μm), such that a larger dis-
tance reflects a lower vascular density. Note that for
CD31 analysis one JIMT-1 tumor was removed from
each of the gefitinib and RAD001-gefitinib combination
groups due to the presence of disproportionate necrosis;
where only a narrow, avascular rim could be detected as
viable tissue. To observe the location of proliferating
cells in relation to blood vessels, Ki67 positive pixels
were sorted based on their distance from CD31-positive
vessels in 1.5 μm increments, and data are expressed as
% positive Ki67 pixels relative to distance from vascula-
ture (μm).
Statistical analysis
One-way ANOVA was used to assess differences among
the treatment groups with an unpaired t-test (GraphPad
Prism version 5.00). The obtained p values were
adjusted for multiple comparisons using the Benjamini-
Hochberg procedure (R version 2.11.1). Differences were
considered significant at p ≤ 0.05.
Results
Gefitinib and RAD001 in combination synergistically
decrease tumor cell viability in vitro
The efficacy of gefitinib, RAD001, or the combination
was investigated in HER2 overexpressing TZ sensitive
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PIK3CA gene encoding the p110-alpha catalytic subunit
of PI3K), TZ sensitive MCF7-HER2 cells (ER positive,
PTEN positive, mutated PIK3CA gene) and TZ resistant
JIMT-1 cells (ER negative, PTEN positive, mutated
PIK3CA gene) [12,38,42,43]. Overexpression of HER2 in
S K B R 3a n dJ I M T - 1c e l l si sd u et oe n d o g e n o u sg e n e
amplification while the MCF7-HER2 cells have been
transfected with the erbB2 gene driven by the CMV
promoter. The three cell lines co-express EGFR, with
the highest protein levels noted in JIMT-1 cells (Figure
1A). The expression of HER-3 protein was highest in
MCF7-HER2 and relatively low in SKBR3 and JIMT-1
cells and P-AKT was constitutively expressed in all
three cell lines (Figure 1A). Using an Alamar Blue assay
to assess cell viability, we determined the cell fraction
affected (Fa) by each treatment following a 72 h or 144
h exposure to the drugs alone and in combination. After
72 h viability decreased in response to a broad range of
gefitinib or RAD001 concentrations in all treated cell
lines (Figure 1B). Fa was improved after increasing drug
exposure to 144 h, with the greatest improvement in
SKBR3 cells reflecting their relatively slow proliferation
rates (Figure 1B). The inhibitory concentration of gefiti-
nib and RAD001 which elicited a 50% decrease in cell
viability (IC50), was calculated using CompuSyn™ soft-
w a r eb a s e do nt h eA l a m a rB l u ed a t a .I nJ I M T - 1a n d
MCF7-HER2 cells the IC50 values for RAD001 after 72
h reached 19 ± 2.2 and 10.7 ± 8.1 nM (mean ± SE)
respectively; an IC50 for RAD001 was not achieved in
SKBR3 at this time point. After 144 h treatment the
IC50 values for RAD001 were 5.9 ± 3.7, 6.8 ± 2.5, 5.4 ±
1.9 nM (mean ± SE) in SKBR3, JIMT1 and MCF7-HER2
cells respectively, thus demonstrating that all three cell
lines have a similar sensitivity to RAD001. The dose
response curves for RAD001 showed a concentration
dependent reduction in cell viability up to ~ 3 - 6 nM.
Higher doses of RAD001 resulted in only a small incre-
mental rise in the Fa, suggesting saturation of RAD001
effects (Figure 1B). The IC50 values for gefitinib after 72
h treatment were 4.3 ± 1.2 μM (mean ± SE) in SKBR3
cells and > 10 μM in JIMT-1 and MCF7-HER2 cells;
after 144 h the IC50 values were 1.6 ± 1, 5 ± 0.5 and >
10 μM (mean ± SE) respectively in SKBR3, JIMT-1 and
MCF7-HER2 cells. These results showed that SKBR3
cells were sensitive, JIMT-1 cells were moderately resis-
tant and MCF7-HER2 cells were exceptionally resistant
to gefitinib.
Guided by the IC50 values determined for the single
drugs, the gefitinib and RAD001 combinations were
evaluated at the 50:1, 200:1 and 1000:1 (Gef:RAD) fixed
molar ratios. The effects of the gefitinib and RAD001
combination on cell growth assessed at 200:1 molar
ratio (Gef:RAD) are presented in Figure 1B as an
example of the data showing that the combination
exerted a significantly greater (p < 0.05) growth inhibi-
tion in all three cell lines when compared to the single
drugs at the dose points indicated by asterisks. These
points include therapeutically relevant gefitinib and
RAD001 concentrations that can be achieved in human
blood and which were previously reported as ~1 μMf o r
gefitinib [44] and ~ 5-15 nM for rapamycin and deriva-
tives [45]. The dose response data were then evaluated
with the CompuSyn™ program which applies the med-
ian effect methodology developed by Chou and Talalay
[39] to assess drug-drug interactions. This algorithm
estimates a combination index (CI) for each data point
based on the results expected from each of the single
agents. If the experimental effects of the combination
are greater than expected, then the CI value will be less
than 1. If the experimental effects are less than expected
the CI value will be greater than 1. CI values of 0.8 or
less are indicative of robust synergistic interactions. Fig-
ure 1C shows that after 144 h treatment with the gefiti-
nib and RAD001 combination, a CI < 0.8 was reported
over a wide range of Fa regardless of the drug:drug ratio
used, reflecting synergistic interactions between gefitinib
and RAD001. Importantly, these data underline the fact
that the gefitinib and RAD001 combination is equally
effective in HER2 overexpressing cells irrespective of
their intrinsic resistance to gefitinib or TZ.
Cytotoxic and cytostatic effects of gefitinib, RAD001 and
the combination in vitro
The mechanisms associated with the synergistic growth
inhibition in vitro by the gefitinib and RAD001 combi-
nation were further investigated using high content
screening (HCS) methods to quantitate viable and dead
cells in cultures stained in situ with DRAQ5 and ETH.
The HCS data showed that 72 h treatment with gefitinib
plus RAD001 caused a significant (p < 0.05) increase in
cytotoxicity in SKBR3 and JIMT-1 cells at multiple
doses (Figure 2A). In MCF7-HER2 cells growth inhibi-
tion by the combination (as shown in Figure 1B) was
accompanied by cytotoxic effects only when drugs were
used at high and physiologically irrelevant concentra-
tions (10 μM gefitinib and 50 nM RAD001) [44,45].
After 144 h treatment with the gefitinib and RAD001
combination, an additional increase in cell death took
place in SKBR3 and JIMT-1 cells but not in MCF7-
HER2 cells (data not shown).
To further investigate the mechanisms of action of the
gefitinib and RAD001 combination we performed flow
cytometric analysis of apoptosis and cell cycle. Cells
w e r et r e a t e df o r7 2hw i t h1μM gefitinib, 5 nM
RAD001 or the combination of both drugs at 200:1
molar ratio (Gef:RAD). There was no significant increase
(p > 0.05) found in Annexin positive PI negative
Dragowska et al. BMC Cancer 2011, 11:420
http://www.biomedcentral.com/1471-2407/11/420
Page 5 of 17B
72 h 144 h
RAD
Gef+RAD
Gef A
72h 144h
S
K
B
R
3
00
0.2
0.6
0.8
1.0
0.4
00
0.2
0.6
0.8
1.0
0.4
* * * *
* *
* * * *
HER2
HER3
EGFR
PͲAKT
AKT
ɴͲactin
d

(
m
e
a
n

±
S
D
)
J
I
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
Gef 
(ȝM)
RAD
(nM)
0.0 0.0
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
0.8
1.0
0.8
1.0
* *
* ** *
* * * * *
*
*
C
S
K
B
R
3
50:1
200:1
1000:1
Gef:RAD
1
3
2
F
r
a
c
t
i
o
n

a
f
f
e
c
t
e
d
I
M
T
Ͳ
1
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
Gef 
(ȝM)
RAD
( M)
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
0.0
0.2
0.6
0.4
0.0
0.2
0.6
0.4 *
*
*
J
I
M
T
Ͳ
t
i
o
n

i
n
d
e
x
00 . 2 0 . 6 0.4 0.8 1.0
3
2
0
50:1
200:1
1000:1
Gef:RAD
M
C
F
7
Ͳ
H
E
R
2
0
5
0
5
2
6
8
9
0
5
1 (nM)
0
5
0
5
2
6
8
9
0
5
1
00
0.2
0.6
0.8
1.0
0.4
00
0.2
0.6
0.8
1.0
0.4
* * * *
*
*
* * * * *
Ͳ
1
M
C
F
7
C
o
m
b
i
n
a
t
3
2
00 . 2 0 . 6 0.4 0.8 1.0
0
1
50:1
200:1
1000:1
Gef:RAD
Drugconcentration
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
Gef 
(ȝM)
RAD
(nM)
2
.
5
1
0
.
0
1
.
2
5
5
.
0
0
.
6
2
5
0
.
3
1
2
0
.
1
5
6
0
.
0
7
8
0
.
0
4
0
0
.
0
1
0
0
.
0
0
2
2
5
.
0
1
2
.
5
5
0
.
0
6
.
2
5
3
.
1
2
1
.
5
6
0
.
7
8
0
.
3
9
0
.
2
0
0
.
0
5
0
.
0
1
0.0 0.0
7
Ͳ
H
E
R
2
Fractionaffected
0
1
00 . 2 0 . 6 0.4 0.8 1.0
Figure 1 Phenotypic analysis and in vitro sensitivity of SKBR3, JIMT-1 and MCF7-HER2 cells to gefitinib, RAD001, or the gefitinib and
RAD001 combination. (A) Expression of HER2, EGFR, HER3, P-AKT and AKT analyzed by Western blotting. (B) Cells were treated for 72 or 144 h
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Page 6 of 17apoptotic cells in SKBR3 or MCF7-HER2 cultures trea-
ted with the combination compared to treatment with
the single drugs at corresponding concentrations (Figure
2B). In JIMT-1 cells treated with the combination there
was a 3-fold increase in apoptosis relative to gefitinib or
RAD001 treatment alone (p < 0.05); however, the abso-
lute percentage of apoptotic cells in the combination
treated cultures was only 4% compared to 1% in the sin-
gle drug treated cultures.
Cells treated in an identical manner as described above
were then analyzed for changes in cell cycle. The data
summarized in Figure 2C show that the gefitinib and
RAD001 combination significantly increased (p < 0.05) the
proportion of cells in G1/G0 and reduced the S phase frac-
tion in SKBR3 and JIMT-1 cells, when compared to either
of the drugs alone. No significant changes in cell cycle (p
> 0.05) were observed in MCF7-HER2 cells (Figure 2C).
Gefitinib and RAD001 in combination decrease activity of
the mTOR pathway in vitro
To investigate the molecular changes in HER2 overex-
pressing breast cancer cells after treatment with the
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Page 7 of 17gefitinib and RAD001 combination, we analyzed the
expression and phosphorylation of proteins relevant to
EGFR, HER2 and mTOR signaling. The focus of this
investigation was to characterize more stable long-term
changes that occurred after 72 h of treatment rather
than assessing immediate effects that may be transient
in nature. The results summarized in Figure 3 show that
treatment with 1 μM gefitinib lowered the levels of P-
EGFR, P-HER2, P-ERK1/2 and P-p70S6K compared to
vehicle treated cells in all three cell lines; inhibition of
P-AKT was observed in SKBR3 and JIMT-1 and inhibi-
tion of P-S6 in SKBR3 and MCF7-HER2 cells (Figure
3A and 3B). RAD001 inhibited activity of mTOR down-
stream targets (P-p70S6K and P-S6) but increased P-
AKT levels relative to the controls in all three cell lines
(Figure 3A and 3B). RAD001 also caused upregulation
of P-EGFR in JIMT-1 cells, P-HER2 in MCF7-HER2
cells and P-ERK1/2 in SKBR3 and MCF7-HER2 cells.
When gefitinib and RAD001 were used in combination
there was a considerably greater reduction noted in P-
p70S6K and P-S6 compared to the single drugs which
was consistent in all three cell lines. A further decrease
in P-ERK1/2 and P-AKT by the combination took place
only in JIMT-1 cells (Figure 3A and 3B). Gefitinib, when
added to RAD001, was also able to counteract RAD001
induced hyperphosphorylation of EGFR, HER2, ERK1/2
and AKT in various cell lines, except for ERK1/2 in
MCF7-HER2 cells (Figure 3A and 3B). These data sug-
gest that inhibition of the mTOR pathway by RAD001 is
enhanced in the presence of gefitinib, which also for the
most part prevented RAD001 induced increases in cer-
tain phosphoproteins. Interestingly, in MCF7-HER2 cells
treated with gefitinib and the combination, a reduction
in P-EGFR, P-HER2 and P-S6 was accompanied by
lower levels of total EGFR, HER2 and S6 (Figure 3A),
and in combination treated JIMT-1 cells a decrease in
P-p70S6K also occurred in parallel to decreased p70S6K
(Figure 3A).
Gefitinib and RAD001 in combination impede growth of
established TZ sensitive and TZ resistant tumors
The in vitro data presented thus far strongly suggest
that the gefitinib and RAD001 combination exerts bene-
ficial therapeutic effects in HER2 overexpressing breast
cancer cell lines, irrespective of their TZ or gefitinib
sensitivity status. To test the efficacy of this combination
in vivo, animals bearing established JIMT-1 and MCF7-
HER2 tumors were treated for 28 and 25 days, respec-
tively, with gefitinib, RAD001 or a combination of the
two drugs. The results summarized in Figure 4A (left
panel) show that JIMT-1 tumors exhibited no change in
growth rate when tumor bearing mice were treated with
12.5 or 50 mg/kg gefitinib, but at 100 mg/kg a moderate
1.3-fold reduction in tumor volume relative to controls
was observed (p > 0.05). When mice bearing established
JIMT-1 tumors were treated with 1.25 mg/kg and 2.5
mg/kg RAD001, there was a 1.2-fold and 1.7-fold
decrease in tumor volume, respectively, when measured
on the last day of treatment, but again, tumor volume
was not significantly different (p > 0.05) from tumors in
the vehicle treated group (Figure 4A, middle panel). For
the combination treatment, doses of 100 mg/kg gefitinib
and 1.25 mg/kg RAD001 were selected, as they provided
a sub-optimal therapy. This approach has a strategic
advantage over using the maximum tolerated doses of
single drugs in combination experiments since it helps
to clearly demonstrate whether combining drugs pro-
vides an improvement in reducing tumor volume. Treat-
ment of animals bearing JIMT-1 tumors with the
gefitinib and RAD001 combination caused a significant
(p < 0.05) 2.5-fold decrease in tumor volume on the last
day of treatment relative to controls; however, these
tumors were not significantly different compared to
tumors harvested from animals treated with gefitinib or
RAD001 alone (p > 0.05) (Figure 4A, right panel).
MCF7-HER2 tumors were more sensitive to gefitinib
and RAD001 than JIMT-1 (Figure 4B). Increasing the
gefitinib dose to 200 mg/kg and RAD001 above 2.5 mg/
kg resulted in a greater therapeutic effect represented by
stable disease rather than tumor regression in animals
bearing MCF7-HER2 tumors (Figure 4B, left and middle
panels). Gefitinib used at 100 mg/kg and RAD001 used
at 1.75 mg/kg reduced tumor volume by 2.7-fold and
1.6-fold, respectively, relative to the vehicle control
group but these differences were not statistically signifi-
cant (p > 0.05) (Figure 4B, right panel). However, the
average MCF7-HER2 tumor volume on the last day of
treatment in the combination treated group was signifi-
cantly smaller (p < 0.05) than in the control or RAD001
group (6.7-fold and 4.3-fold reduction, respectively). In
contrast, the difference between the combination and
gefitinib treated tumors was not statistically significant
(p > 0.05) (Figure 4B, right panel). These data show that
the combination treatment was more potent than the
single drugs when compared to vehicle treated controls.
Importantly, the combination prevented further growth
of TZ sensitive and resistant tumors. The synergy analy-
sis based on the median effect methodology developed
by Chou and Talalay [39] could not be performed on
the in vivo data because the combination was only
tested at one dose of gefitinib.
It should be noted that none of the treatment regi-
mens caused any considerable body weight loss in ani-
mals (p > 0.05). Detailed animal health monitoring data
(not reported here) suggested that gefitinib and RAD001
were well tolerated at the doses used, whether the drugs
were used alone or in combination. It is important to
note that we also tested sensitivity of JIMT-1 tumors to
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Figure 3 In vitro molecular responses to gefitinib, RAD001 and the gefitinib and RAD001 combination. SKBR3, JIMT-1 and MCF7-HER2
cells were treated for 72 h with indicated concentrations of gefitinib (Gef), RAD001 (RAD) or the combination of both drugs at a 200:1 (Gef:RAD)
molar ratio. Cell lysates were prepared from harvested cells and expression of phospho- and corresponding total protein were analyzed with
Western blotting. (A) Representative images of protein bands. (B) The expression of phosphorylated proteins, as shown in (A) was measured by
densitometry and normalized to the vehicle control expressed as 1 and denoted by a dotted line in each histogram. b-actin was used to control
for equal loading. The MDA-MB-468 cell line with a high EGFR and negligible HER2 expression was used to control for specificity of the anti P-
EGFR and P-HER2 antibodies.
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Page 9 of 17TZ in Rag2M mice. The results of this study presented
in “Additional file 1“ show that treatment with TZ (up
to 20 mg/kg given twice weekly (i.p.) over the course of
27 days) did not cause inhibition of tumor volume (p >
0.05), thus, confirming the resistance of JIMT-1 cells to
TZ, as previously determined by others [38].
Effects of gefitinib, RAD001 and the combination on
tumor tissue characteristics
Immunohistochemistry (IHC) based tumor tissue map-
ping techniques were used to investigate changes in
JIMT-1 tumors harvested from animals treated for 28
days with 100 mg/kg gefitinib, 1.25 mg/kg RAD001 or
the gefitinib and RAD001 combination and in MCF7-
HER2 tumors harvested from animals treated for 25
days with 100 mg/kg gefitinib, 1.75 mg/kg RAD001 or
the combination. The area of confluent TUNEL-positive
tissue, herein described as “necrosis” (Figure 5A, left
panel) and TUNEL staining within regions of viable
tumor tissue, indicative of apoptotic cells, along with
CD31 staining and proliferation status (Ki67) of tumor
tissue were assessed (Figure 5A, middle and right panel).
The results indicate that the mean level of necrosis (Fig-
ure 5B, a and 5d) and apoptosis (Figure 5B, b and 5e)
did not differ between treatment groups (p > 0.05) in
JIMT-1 and MCF7-HER2 tumors. Because gefitinib and
RAD001 have been reported to exert anti-angiogenic
effects [21,36,46,47], we also investigated possible
changes in tumor vascularization. An overall higher ves-
sel density was seen in the MCF7-HER2 tumors where
the median distance of tumor tissue to the nearest
CD31-positive object (vessel) was ~ half that of the
JIMT-1 tumors (Figure 5B, c and 5f). The median dis-
tance of tumor tissue to the nearest CD31-positive ves-
sel in JIMT-1 tumors derived from animals treated with
gefitinib was significantly (p < 0.05) decreased compared
to vehicle control suggesting an increase in vasculariza-
tion. No changes were noticed in tumors derived from
animals treated with RAD001 alone (p > 0.05) and the
combination for the most part reflected the effects of
gefitinib (Figure 5B, c). In MCF7-HER2 tumors, gefiti-
nib, RAD001 and the combination did not produce any
significant (p > 0.05) changes in vascularization relative
to the vehicle control (Figure 5B, f).
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Figure 5 Immunohistochemical analysis of tumor tissue sections. (A) Left panel: representative image of a whole tumor section stained with
anti-CD31 antibody (blue), Hoechst 33342 (gray), and TUNEL (red) to label vasculature, nuclei and apoptosis, respectively. Vast red areas in tumor tissue
represent continuous apoptosis regions, referred to as “necrosis”. Middle panel: a magnified image of a viable area in tumor tissue section shown in
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Page 11 of 17Evidence presented in Figure 5B suggests that tumor
growth inhibition by the gefitinib and RAD001 combi-
nation is not associated with an increase in either necro-
sis or apoptosis. To find out if the growth inhibition is a
result of altered proliferation rates of tumor cells, we
analyzed the expression of Ki67 in tumor sections. Fig-
ure 5C (left graph) shows that in JIMT-1 tumors the
combination caused a significant reduction in Ki67
expressing tissue (p < 0.05; 2.5-fold) compared to vehi-
cle treated controls. This is in contrast to the single
drugs which did not produced a significant reduction in
Ki67 relative to the control group (p > 0.05). In MCF7-
HER2 tumors the expression of Ki67 was significantly
lower (p < 0.05) in the combination treated group com-
pared to vehicle (1.5-fold decrease) and also to the sin-
gle drug treated groups (1.9-fold and 1.5-fold decrease
compared to gefitinib and RAD001 group, respectively)
(Figure 5C, right graph).
When these differences were further investigated by
mapping the micro-regional distribution of Ki67 positive
pixels relative to CD31-stained vessels, more specific
detail was obtained. In JIMT-1 tumors, decreased Ki67
staining was observed in all treatment groups relative to
controls and at all distances from vasculature, with the
combination showing the greatest effect at tumor tissue
in close proximity to vessels (Figure 5D, left graph). A
different pattern was observed in MCF7-HER2 tumors,
where RAD001 showed no major change relative to con-
trols but gefitinib alone caused a remarkable increase in
proliferation both at near proximity and > 100 μMf r o m
the vessels. In MCF7-HER2 tumors the combination
treatment was the only regimen to affect a drastic
decrease in proliferation in tissue proximal to vascula-
ture which, similarly to gefitinib treatment alone, did
not decrease further with growing distance from vessels
(Figure 5D, right graph). In summary, these data provide
evidence that gefitinib and RAD001 when used in com-
bination in vivo do not increase cytotoxicity but interact
to increase cytostasis, with greater effects in tumor tis-
sue proximal to vasculature.
Gefitinib and RAD001 in combination decrease levels of
P-EGFR and inhibit the mTOR pathway in vivo
To assess molecular changes in JIMT-1 and MCF7-
HER2 tumors harvested from treated animals, tumor tis-
sue lysates were analyzed with Western blotting. The
results summarized in Figure 6 show protein bands (Fig-
ure 6A) and optical density of each band corrected for
b-actin expression and normalized to the vehicle control
(Figure 6B). Gefitinib treatment resulted in decreased P-
EGFR, P-ERK1/2 and P-S6 levels, relative to vehicle con-
trols, in MCF7-HER2 and JIMT-1 tumors (Figure 6A
and 6B). In addition, gefitinib caused a decrease in P-
HER2, P-AKT and P-p70S6K levels in MCF7-HER2
tumors (Figure 6A and 6B). Targeting the mTOR path-
way with RAD001 brought about a decrease in P-
p70S6K and, interestingly, also a decrease in P-EGFR
and P-HER2 levels in JIMT-1 and MCF7-HER2 tumors.
P-S6 was inhibited only in JIMT-1 tumors and there
were no noteworthy changes in P-AKT after treatment
with RAD001 (Figure 6A and 6B). Addition of gefitinib
to RAD001 resulted in greater inhibition of P-EGFR, P-
p70S6K and P-S6 in both JIMT-1 and MCF7-HER2
tumors (Figure 6A and 6B) compared to the single
drugs. In contrast, the combination exerted a reduction
in P-ERK1/2 and P-AKT that was very moderate and
tumor type specific (Figure 6B). The results also show
that total EGFR, HER2, p70S6K and S6 protein expres-
sion in tumors treated with the combination was
decreased in parallel to levels of corresponding phos-
phoproteins in JIMT-1 and MCF7-HER2 tumors (Figure
6A). Gefitinib also caused a drastic decrease in total
EGFR and somewhat smaller decrease in HER2 in
MCF7-HER2 tumors (Figure 6A). Overall, these data
suggest that the gefitinib and RAD001 combination in
vivo reduces activity of EGFR, p70S6K and S6 through
inhibiting function as well as decreasing expression of
these proteins.
Discussion
New treatment strategies are needed for patients with
advanced HER2-positive breast cancers due to very lim-
ited therapeutic options available for fighting this dis-
ease. Encouraged by previously published reports
demonstrating synergistic interactions between EGFR
and mTOR inhibitors in various cancers [34-36] we
investigated the activity of the EGFR targeted drug gefi-
tinib used in combination with a rapamycin analog,
RAD001, in HER2 overexpressing and EGFR co-expres-
sing breast cancer models with TZ sensitive or resistant
phenotypes [12,38,42,43]. The rationale to study this
combination in HER2 positive breast cancers has also
been strengthened by a recent investigation of Miller et
al. who demonstrated that inhibition of PI3K and
mTOR are required for the growth inhibitory effects of
HER2 antagonists in HER2 overexpressing breast cancer
and that inhibition of mTOR is an effective therapeutic
strategy in TZ resistant breast cancer models [48].
Our data showed that while SKBR3 cells were sensitive
to gefitinib, JIMT-1 and MCF7-HER2 cells were gefitinib
resistant; however, RAD001 was capable of sensitizing
these cells to gefitinib. It is interesting to note that both
JIMT-1 and MCF7-HER2 cell lines harbor PIK3CA
mutations which have been associated with acquired
resistance to EGFR kinase inhibitors but can also predict
sensitivity towards mTOR inhibition [43,49,50]. Together
with our data, this may suggest that RAD001 is able to
reverse gefitinib resistance in PIK3CA mutant tumors.
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Figure 6 In vivo molecular responses to gefitinib, RAD001 and the gefitinib and RAD001 combination. Western blot analysis of phospho-
and corresponding total protein levels in tissue lysates derived from JIMT-1 and MCF7-HER2 tumors harvested from Rag2M mice at the end of
treatment. Animals bearing JIMT-1 tumors were treated with 100 mg/kg gefitinib (Gef), 1.25 mg/kg RAD001 (RAD) and the combination of both
drugs and animals bearing MCF7-HER2 were treated with 100 mg/kg gefitinib, 1.75 mg/kg RAD001 and the combination of both drugs. Protein
concentration in tumor tissue lysates from individual tumors was adjusted to 50 mg/ml and an equal volume of each individual tumor lysate
was pooled for loading gels. Results from six pooled tumor lysates per lane are shown. (A) Representative images of protein bands. (B) The
phosphoprotein levels shown in (A) relative to b-actin were determined by densitometry and normalized to the vehicle control expressed as 1
and denoted by a dotted line in each histogram.
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interact in a synergistic fashion, as shown by a mathema-
tical model developed by Chou and Talaly [39] and this
synergy did not appear to be drug ratio dependent. The
in vivo efficacy of gefitinib and RAD001 was also greatly
improved when these drugs were used in combination.
Further validation of our results in other models of HER2
overexpressing and TZ resistant breast cancers such as
MDA-MB-453, MDA-MB-361 or UACC893 would be
crucial in order to determine if this combination is
broadly effective in TZ resistant cancers. However, our
results obtained using the JIMT-1 model do give an indi-
cation that the gefitinib and RAD001 combination was
able to effectively target the cellular machinery that is
indispensable for cancer cell growth despite the existence
of multiple mechanisms contributing to the extreme TZ
resistance of this cell line [38,42]. It should be noted that
while the combination treatment did not result in regres-
sion of established tumors, this could be a consequence
of our experimental design. We opted to use doses of
gefitinib and RAD001 that on their own did not produce
statistically significant (p > 0.05) reduction in tumor
volume relative to vehicle treated controls, so that inhibi-
tion of tumor growth by the combination would be evi-
dent. Consequently, gefitinib given at 100 mg/kg resulted
in a more potent reduction in MCF7-HER2 tumor
volume than anticipated on its own, thus making the
effect of the combination very modest.
The data obtained based on analysis of multiple end-
points after 72 h treatment suggest a contribution of
cytostasis in the presence (in SKBR3 and JIMT-1 cells)
or absence (in MCF7-HER2 cells) of cytotoxicity to the
synergy between gefitinib and RAD001 in vitro.T r e a t -
ment with the combination induced apoptosis only in
JIMT-1 cells; however, it should be noted that Annexin
V is a marker for the early apoptotic event so apoptosis
may not be detected in SKBR3 and MCF7-HER2 cells
after 72 h. Thus, a contribution of apoptosis to cytotoxi-
city at earlier time points is possible. Our findings are
consistent with other reports demonstrating that gefiti-
nib and RAD001 are cytostatic in nature [12,14,25,45]
and that the degree of cytotoxicity triggered by these
drugs is a cell type dependent phenomenon [14,48].
This perhaps reflects PIK3CA or other mutations in
genes controlling cell growth, proliferation and survival
[43]. While the enhancement of cytostasis seen after 72
hi nt h ec o m b i n a t i o n( 1μM gefitinib with 5 nM
RAD001) treated SKBR3 and JIMT-1 cells was con-
firmed by increased G1/G0 cell cycle arrest and
decreased S phase relative to the single drugs, the com-
bination failed to induce significant cell cycle changes in
MCF7-HER2 cells despite growth inhibition in the
absence of cytotoxicity. It has been reported that the
parental MCF7 cell line expresses high levels of
activated p70S6K and cyclin D1 [51] which may have
contributed to somewhat obscure cell cycle regulation,
possibly resulting in longer time required to complete a
cell cycle or perhaps a transient cell cycle block that
was resolved before 72 h. Increased cytostasis by the
gefitinib and RAD001 combination in the absence of
increased cytotoxicity was also found in vivo in JIMT-1
and MCF7-HER2 tumor xenografts. This may explain
why the combination stabilized tumor growth and did
not cause tumor regression. Interestingly, gefitinib
increased levels of Ki67-positive cells in MCF7-HER2
tumors. These proliferating cells were present at similar
frequency in proximal and longer (> 100 μM) distances
from the blood vessels suggesting that tissue perfusion
in gefitinib treated tumors was perhaps improved. In
support, our previous study found that MCF7-HER2
tumors treated with gefitinib contain a greater propor-
tion of functional Hoechst 33342 perfused vessels and
this correlated with significantly increased tumor tissue
oxygenation resulting in fewer hypoxic cells present
[52]. The study of Lu et al. also showed that positive
therapeutic responses of cancer cells to EGFR-targeted
therapy with cetuximab and gefitinib are associated with
downregulation of hypoxia-inducable-factor-1a (HIF-1
a) [53]. Furthermore, Hardee et al. reported that block-
ade of HER2 signaling in MCF7-HER2 tumors with TZ
improved tumor tissue oxygenation and vascular archi-
tecture along with increased microvessel density [54].
Thus, we speculate that gefitinib treatment perhaps
resulted in vessel normalization. In turn, improved ves-
sel functionality could be responsible for more efficient
delivery of drugs to tumor tissue and increased cytosta-
sis. This may explain why MCF7-HER2 tumors were
more sensitive to gefitinib than JIMT-1 tumors, even
though we found the opposite to be true in vitro in
MCF7-HER2 and JIMT-1 cells.
The most striking and consistent therapeutic effect of
the combination noted in vitro and in vivo was greater
inhibition of the mTOR pathway reflected by decreased P-
p70S6K and P-S6 levels relative to the effects of the single
drugs. These changes strongly correlated with better effi-
cacy of the combination treatment. Accordingly, several
reports suggested that P-p70S6K can be considered as a
biomarker for monitoring treatment outcomes in patients
receiving mTOR inhibitors [25,45,55,56]. While the com-
bination did not decrease P-EGFR levels in vitro compared
to the single drugs, enhanced inhibition of P-EGFR by the
combination in vivo appeared to be a consistent molecular
event in JIMT-1 and MCF7-HER2 tumors. This can be
attributed to inhibition of P-EGFR by both gefitinib and
RAD001. The latter effect was not reported in other stu-
dies and the mechanisms involved are unclear at this
point. Improved inhibition of P-EGFR by the combination
in vivo may certainly play a role in downregulation of the
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inhibition of AKT and ERK1/2 activity remains a question
for further research. Interestingly, the in vivo reduction in
P-EGFR, P-HER2, P-p70S6K and P-S6 levels was mirrored
by decreases in total expression of the corresponding pro-
teins in different treatment groups. Similar correlations
were observed in vitro for selected proteins in gefitinib
and/or combination treated MCF7-HER2 and JIMT-1
cells. These data suggest that inhibition of translation rates
or perhaps changes in post-translational events regulating
the expression of EGFR, HER2, p70S6K and S6 proteins
may have contributed to decreased signaling in addition to
direct effects on protein phosphorylation. In contrast, the
expression of ERK1/2 and AKT in vivo was not altered
after different treatments indicating that changes in phos-
phorylation levels actually reflected activation status of
these proteins.
It should be noted that despite greatly improved inhibi-
tion of the mTOR pathway by the gefitinib and RAD001
combination our data suggest lack of or only moderate
inhibitory effects of the combination on P-AKT levels.
This result can be explained by a RAD001 mediated nega-
tive feedback loop. It has been demonstrated that inhibi-
tion of mTORC1 by rapamycin analogs initiates p70S6K-
dependent feedback signaling resulting in stimulation of
mTORC2 and phosphorylation of AKT on Ser473 [24-30].
Our in vitro data show that after 72 h RAD001 increased
P-AKT levels in all three cell lines, but addition of gefitinib
to RAD001 was able to counteract this effect. RAD001
also enhanced P-ERK1/2 levels in SKBR3 and MCF7-
HER2 cells and in JIMT-1 tumors and these results are in
agreement with studies showing activation of ERK1/2
through a PI3K-dependent feedback loop following inhibi-
tion of mTORC1 in some human cancers [57]. Again,
addition of gefitinib to RAD001 counteracted activation of
ERK1/2 in SKBR3 cells and in JIMT-1 tumors. Nonethe-
less, absence of robust inhibition of AKT and ERK1/2
activity in vivo after treatment with the combination is of
concern since it may provide cancer cells with a survival
advantage and lead to development of drug resistance and
escape from cytostasis which consequently would limit
treatment efficacy [3-5,18,58,59]. Likewise, other investiga-
tors have shown that targeting HER2 and mTOR using
the TZ and RAD001 combination inhibits growth of
HER2 overexpressing cancers to a greater extent than sin-
gle agents, but this treatment did not further reduce P-
AKT or P-ERK1/2 levels, when compared to the single
drug effects [48]. Thus, combining drugs that inhibit func-
tion of EGFR/HER2 with dual PI3K/mTOR and MEK
pathway inhibitors in order to abolish compensatory
mechanisms may eliminate cancer cell survival and per-
haps improve therapeutic effects in HER2-positive breast
cancers [59-62].
Conclusions
In summary, we showed that the gefitinib and
RAD001 combination is therapeutically effective in
HER2 overexpressing breast cancers irrespective of
their TZ or gefitinib sensitivity status. The combina-
tion increased inhibition of cancer growth in vitro and
in vivo. The beneficial therapeutic effects of gefitinib
and RAD001 when used in combination appear to be
related to ability of drugs to achieve efficient inhibi-
tion of mTOR (in vitro and in vivo)a n dE G F R( in
vivo) signaling while at the same time eliminating
negative feedback effects. Because the gefitinib and
RAD001 combination shows a favorable safety profile
in vivo and both drugs are approved for human use,
this combination could be rapidly translated into
opportunities in the clinic.
Additional material
Additional file 1: Efficacy of TZ in JIMT-1 tumors. JIMT-1 xenografts (s.
c.) were established in Rag2M mice and animals were treated with
vehicle (saline) or 2.5, 5, 10 and 20 mg/kg trastuzumab (TZ) (n = 6
animals/treatment group). Treatment was initiated on day 21 and
administered as intra-peritoneal injections (i.p.) twice weekly for 4 weeks.
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